Connect with us

Business

Global WholeHealth Partners Corp (OTC: GWHP) Has Paid Off Another of Its Outstanding Convertible Notes as Stated in the 8K Filed on 02/17/21

Published

on

Global WholeHealth Partners Corp (OTC: GWHP), has paid off another of its outstanding convertible notes as stated in the 8K filed on 02/17/21. The note was paid from a direct equity investment by a healthcare investor.

Eliminating the second convertible note represents a significant milestone for Global WholeHealth Partners Corp (OTC:GWHP); Global will seek capital from longer term investments. Global is building a stronger financial base, by eliminating debt. Since the note was not converted into shares under the original terms, we were also able to avoid substantial dilution to our shareholders.

 

Given our outlook for strong growth this year and the rapidly improving fundamentals of the business, Global is getting into a position where we hopefully can fund our growth from cash flow from operations or from capital equity sources.

The strong growth outlook comes from Global leading the way in the fight against CoViD19, by offering 15 Minute Rapid IgG/IgM Tests for Venous Blood, & Fingertip Blood (POC), and 90 Minute rt-PCR Tests for CoViD19 with All the Tests Being FDA EUA Authorized, one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2.

About Global WholeHealth Partners Corp.:

Global WholeHealth Partners Corp, knowing that the next step in the fight against CoViD19 SARS2 is the Antigen test, has already filed with the FDA the PEUA Application # PEUA201789 for the Rapid 10 minute Nasal Antigen Test. Global’s version of the Antigen test does not need a machine to read the results.

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.

With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingertip test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.

Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, “The Company’s goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like Rapid Ebola, ZIKA, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests. Global is planning to be able to offer an Antigen Rapid Test soon.”

Global WholeHealth Partners Corp (GWHP: OTC) offers all the formats for testing CoViD 19 SARS 2. Global has the Antibody IgG/IgM Rapid antibody, including the POC (Point of Care), the rtPCR CoViD 19 SARS test, which works on any machine; these entire tests are FDA EUA AUTHORIZED.

Global also offers for international sales the Antigen Rapid IgA test, which is not FDA EUA Authorized.

Call 1-877-568-GWHP (4947) to become a distributor or buy FDA EUA Authorized SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test kits, or the Point of Care IgG/IgM fingertip blood format or the rtPCR test.

For more details: https://gwhpcorp.com

Media Contact:

Name: Charles Strongo,

CEO, Global WholeHealth Partners Corp.

Email: Sales@gwhpcorp.com

Symbol: GHWP

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Continue Reading
Advertisement

Business

WynCore Offers Warehouse Management System Optimization Services to Businesses

Published

on

By

With all the changes in the delivery and ordering processes, your company needs a customized approach to upgrading WMS to optimize results. Your confident choice to provide these services is WynCore. We provide customized warehouse management system modifications for Manhattan Software. For more information, get in touch with WynCore today to speak with our software developers about your warehouse management software upgrade services and customization needs by calling us at 866-996-2673.

With over 50 years of combined experience in the industry, we are known as a leader in WMS configurations, providing you with a full host of services including: design and implementation, QA Testing, customized maintenance, support and training. We can craft your WMS optimization plan in a cost-effective package to suit your business.

We know that running a business smoothly and efficiently directly affects your bottom line. Our expert software developers design a customized modification or upgrade to assist you in operating your warehouse flawlessly. From minor tweaks and adjustments to your WMS or complete redesign, WynCore consultants craft your ideal solution.

In addition, we are proud to note that our developers and project management teams are experts in both Agile and Waterfall methodologies and well versed in DEV-OPS and in training your staff.

Our support to you does not stop at the end of your WMS customization services. Our project management and global support team provides assistance whenever you needed it to help minimize disruptions with any arising issue after completing your WMS modifications.

Your investment in optimizing begins with your choice of WyCore. We know the WMS business inside and out and offer a team of experts that  can provide all you want within the budget and timeline that you need to meet. From a small adjustment or modification to a major overhaul our consultants provide the plan, implantation and support for your custom needs. Why delay? Speak with our software developers about your warehouse management software upgrade services and customization needs by calling us at 866-996-2673.

Continue Reading

Business

Purchase Superior COVID-19 Diagnostic Testing Kits And Personal Protective Equipment Online from Global WholeHealth Partners

Published

on

By

Searching for and finding in stock PPE supplies and COVID-19 diagnostic testing kits online is easy when you shop Global WholeHealth Partners. As COVID-19 cases increase as a result of the Delta Variant, we continue to source and supply these in demand products. Even in the midst of the pandemic, we are able to supply these products as a result of our standing partnerships with key players in the industry.

As vaccines are making their way to millions of Americans and people worldwide, we are hopeful that COVID-19 cases will begin to decline. However, the use of PPE supplies remains high as domestic and international travel increases as well as more and more retail stores and restaurants begin to open.

We all can do our part to help slow the spread of COVID-19 by social distancing where we can, staying quarantined when we are sick, and using PPE supplies when leaving the house. Masks wearing is required in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

Browse our medical supply page today to view current inventory and offerings. Remember, GWHP Corp sources and supplies the best PPE supplies and COVID-19 diagnostic testing kits. We are proud to be able to source and supply these in demand products in wholesale quantities during these trying times. Get in touch with us today by calling 877-568-4947.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading

Business

GWHP Corp Sources Wholesale PPE Supplies and COVID 19 Testing Kits In The Age of Coronavirus and Rising COVID-19 Cases

Published

on

By

With many states and countries still facing lockdowns, social distancing measures and required use of PPE gear, Global WholeHeath Partners recognizes that demand is still high for COVID-19 diagnostic testing kits and PPE supplies. We are proud to announce that our standing relationships and partnerships with key players in the industry enable us to source and supply large quantities of these in demand products. Visit our medical supply page online today to view current offerings. We are happy to provide fast fulfillment times on your wholesale orders as well.

We all can do our part to help slow the spread of COVID-19 by social distancing where we can, staying quarantined when we are sick, and using PPE supplies when leaving the house. Masks wearing is required in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

Even as the Pfizer and Moderna vaccine are making their way to millions of people across the globe, continued use of PPE supplies will help slow the spread of the virus so we can end this pandemic.

To place your wholesale order of PPE supplies or COVID-19 diagnostic testing kits get in touch with us today. Global WholeHealth Partners stands committed to sourcing these in demand products for interested parties in wholesale capacities. Visit our medical supply page to view current offerings and get in touch with us to place your wholesale order, call 877-568-4947.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading

Trending